Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Akari Therapeutics plc ADR (0.01 USD)

AKTX

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $6.08 – $6.33
Volume 8,686
Market cap $15M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$14.88M
Price / earnings
—
Price / book
0.85×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.57×

Profitability

Earnings per share
-$12.87
Return on assets
-80.38%
Return on equity
-168%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
0.48×
Quick ratio
0.48×
Cash ratio
0.44×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.86M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for AKTX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$2.57M$2.53M$2.17M$2.14M$1.98M$2.45M$2.71M$3.05M
Research and development$2.11M$2.08M$1.46M$1.09M$249K$667K$813K$1.25M
Total operating expenses$4.68M$4.6M$15.76M$3.23M$7.4M$3.12M$3.53M$5.28M
Operating income-$4.68M-$4.6M-$15.76M-$3.23M-$7.4M-$3.12M-$3.53M-$5.28M
Interest expense-$85K-$80K-$61K-$723K-$121K-$50K-$55K-$124K
Income before taxes-$4.84M-$4.81M-$15.31M-$5.21M-$7.49M-$1.9M-$3.71M-$3.77M
Income taxes$0$0-$859K$85K-$1.09M$0$0$0
Net income-$4.84M-$4.81M-$14.46M-$5.3M-$6.4M-$1.9M-$3.71M-$3.77M
Net income attributable to common shareholders-$4.84M-$4.81M-$14.46M-$5.3M-$6.4M-$1.9M-$3.71M-$3.77M
EBITDA-$4.68M-$4.6M-$3.63M-$3.23M-$2.22M-$3.12M-$3.53M-$4.29M
Basic earnings per share$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Diluted earnings per share$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation

Akari Therapeutics announced a strategic research collaboration with WhiteHawk Therapeutics to combine Akari's PH1 spliceosome-modulating payload with WhiteHawk's TOP1 inhibitor ADC platform for a novel dual-payload strategy. The company is advancing its lead candidate AKTX-101 toward Phase 1 clinical evaluation by mid-2027 and emphasizes that collaborations will play an increasingly important role in advancing next-generation ADC innovation.

GlobeNewswire Inc.

Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026

Akari Therapeutics announced progress in 2025 and outlined its path toward clinical transition in 2026. The company established a manufacturing partnership with WuXi Biologics and initiated pre-filing activities, with plans to launch its First-in-Human clinical trial by late 2026/early 2027. The company's lead candidate AKTX-101 is an ADC targeting Trop2 with a novel PH1 spliceosome-modulating payload designed to deliver dual mechanisms of action: direct tumor cytotoxicity and immune activation.

Benzinga

Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

Akari Therapeutics has successfully completed the merger with Peak Bio, creating an innovative biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. The combined entity secured $3.2 million in PIPE financing and a $50 million term sheet for an equity line of credit to support its pipeline development.

GlobeNewswire Inc.

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics

BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced leadership changes, including the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D. as interim CEO.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Mar 31, 20261-for-40reverse split
Aug 17, 20231-for-20reverse split
Sep 17, 20151-for-10reverse split